AC
STOK icon

Athanor Capital’s Stoke Therapeutics STOK Stock Holding History

Athanor Capital’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-6,415
Closed -$397K – 1030
2020
Q4 		$397K Sell
6,415
-2,515
-28% -$115K 0.01% 520
2020
Q3 		$299K Sell
8,930
-4,125
-32% -$118K 0.01% 431
2020
Q2 		$311K Buy
+13,055
New +$310K 0.02% 407
2020
Q1 		– Sell
-9,657
Closed -$273K – 324
2019
Q4 		$273K Sell
9,657
-4,543
-32% -$114K 0.01% 321
2019
Q3 		$305K Buy
+14,200
New +$396K 0.02% 188

Other funds holding STOK

ALSV
ATP Life Science Ventures New York $898M AUM 84.86% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Athanor Capital's STOK Position: Q1 2021 in Review

Athanor Capital sold out of Stoke Therapeutics (STOK) in Q1 2021, closing a stake of 6,415 shares — an estimated $397K sold.

Athanor Capital first reported a position in STOK in Q3 2019 and held it in 5 quarters. The position peaked at $397K in Q4 2020. 106 funds tracked by Wall St. Rank hold STOK as of Q1 2021.

  • Athanor Capital reported no remaining Stoke Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Athanor Capital sold 6,415 Stoke Therapeutics shares in Q1 2021, an estimated $397K.
  • Athanor Capital first reported a position in Stoke Therapeutics in Q3 2019 and held it in 5 quarters.
  • Athanor Capital's Stoke Therapeutics position peaked at $397K in Q4 2020.
  • 106 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q1 2021.

Based on Athanor Capital's 13F filing for Q1 2021, filed 14 May 2021.